Clinical Trial: Study of Serplulimab Plus Chemotherapy as Neoadjuvant Therapy for Limited-stage Small Cell Lung Cancer (LS-SCLC)

U.S., April 5 -- ClinicalTrials.gov registry received information related to the study (NCT06911606) titled 'Study of Serplulimab Plus Chemotherapy as Neoadjuvant Therapy for Limited-stage Small Cell Lung Cancer (LS-SCLC)' on March 10.

Brief Summary: This investigator-initiated, open-label, prospective Phase II clinical trial, planned to take place across multiple centers in China. We aimed to evaluate the efficacy and safety of surgical resection or chemotherapy following serplulimab plus platinum-containing dual induction therapy for stage II-IIIB (N2) LS-SCLC

Study Start Date: May 22, 2024

Study Type: INTERVENTIONAL

Condition: SCLC, Limited Stage

Intervention: DRUG: 4 cycles of Serplulimab combined with etoposide and carboplatin o...